Thanks bella!Just some thoughts from me end - I think this is...

Thanks bella!

Just some thoughts from me end -
I think this is the first time we have seen US licence negotiations mentioned as advancing to execution, in the last AGM when we asked Richard why it was taking so long he did mention the bigger the partner the more complicated the negotiation and agreement, so I still hold high hopes for a solid US partnership.I strongly suspect this partnership is dependant on FDA approval since everything else is ready from a manufacturing and distribution perspective.

Underlying technology seems to continue to improve with the ability to now predict late stage CKD, but sadly this would mean more validation studies.. more time and more funding. But, also means more revenue potential and future moat.

Italy termination, well this sounds all too familiar.. remember what happened back in 2018 with PrismHealth? It sounds like certain promises were made by Medical Horizon to deliver sales, but they failed to meet them and thus Ricard and co decided to terminate the agreement.

So they mention they now have a new assessment process to qualify distributors…and well... this is where we see some of the weakness in our management team.. why has it taken multiple failed distributors to realise the need for better screening of distributors? honestly I was never impressed with the distributors Richard has been partnering with, most of them had very limited public information. But the question in my mind is wether it really is a case of poorly selected distributors not having the correct capabilities, or is PromarkerD just too ahead of its time and or not appealing to physicians?

Interestingly RNLX have been doing OK with KidneyIntelX and generating sales (though it's all through their Mt Sinai's network who were the original founders of KidneyIntelX, so a little bit of bias there) however its very optimistic to see physicians starting to use predictive testing as part of their standard of care.

The key catalysts remain insurance coverage and regulatory approvals, I am prepared to wait for those, meanwhile I still feel positive overall thanks to the potential of other tests in the pipeline (Endo etc). Sadly CR seems imminent, but PIQ is a good business with good products and technology - building a billion dollar business does not happen overnight, it will take time.

For those wondering, I am in touch with OwlvsFox and she did sell out due to the ongoing delays with FDA submission. She will buy back once she see's progress being made. I still remain invested with 100k+ shares, may pick up more if a SPP happens or we take a significant dive.

Fingers crossed guys!